A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy-Reference-Cited by-同舟云学术

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Published:2011-05-19 Issue:3 Volume:30 Page:1216-1223
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Bodoky György,Timcheva Constanta,Spigel David Robert,La Stella Phillip Joseph,Ciuleanu Tudor Eliade,Pover G.,Tebbutt N. C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-011-9687-4.pdf

Reference33 articles.

1. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592

2. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

3. American Cancer Society (2010) Cancer facts & figures 2009. http://www.cancer.org/acs/groups/content/@nho/documents/document/500809webpdf.pdf . Accessed October 2010

4. NCCN Practice Guidelines in OncologyTM (2010) Pancreatic adenocarcinoma (version 2.2010). Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines asp. Accessed October 2010

5. Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160–164

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

2. Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression—A Scoping Review;Cancers;2024-08-22

3. Selumetinib—A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis;Indian Dermatology Online Journal;2024-06-26

4. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment;Frontiers in Oncology;2024-05-10

5. Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review;Frontiers in Bioscience-Landmark;2024-03-13